Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.05	$0.07	$0.02 ▼ $0.78	$2.26M	1.17	4,709 shs	77 shs
CANF Can-Fite BioPharma	$0.66 +3.5%	$0.92	$0.63 ▼ $3.12	$2.33M	1.02	210,608 shs	347,355 shs
ORPN Bioblast Pharma	$1.05 -16.0%	$19.65	$6.16 ▼ $30.00	$441K	1.41	N/A	2.93 million shs
VCNX Vaccinex	$0.53 +26.0%	$0.79	$0.25 ▼ $1.40	$1.38M	1.1	3,066 shs	247 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	+3.92%	+59.16%	+41.33%	+165.00%
CANF Can-Fite BioPharma	-3.85%	-3.86%	-38.70%	-38.75%	-73.84%
ORPN Bioblast Pharma	-31.32%	-14.97%	+5.04%	+26.26%	-0.86%
VCNX Vaccinex	-46.10%	-39.77%	-53.62%	-36.05%	-91.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	1.9668 of 5 stars	3.5	2.0	0.0	0.0	1.1	0.0	1.3
ORPN Bioblast Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	0.5182 of 5 stars	0.0	4.0	0.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
CANF Can-Fite BioPharma	3.00	Buy	$14.00	2,070.54% Upside
ORPN Bioblast Pharma	0.00	N/A	N/A	N/A
VCNX Vaccinex	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORPN, CANF, ADXS, and VCNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	0.70	N/A	N/A	($2.06) per share	-0.03
CANF Can-Fite BioPharma	$674K	3.39	N/A	N/A	$1.76 per share	0.37
ORPN Bioblast Pharma	N/A	N/A	N/A	N/A	$7.56 per share	N/A
VCNX Vaccinex	$388K	2.83	N/A	N/A	($2.59) per share	-0.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$7.98	N/A	∞	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORPN Bioblast Pharma	-$5.94M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	-$20.25M	-$48.27	N/A	∞	N/A	N/A	N/A	-383.58%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
ORPN Bioblast Pharma	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	2.93	N/A
ORPN Bioblast Pharma	N/A	N/A	N/A
VCNX Vaccinex	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
CANF Can-Fite BioPharma	21.00%
ORPN Bioblast Pharma	4.47%
VCNX Vaccinex	50.11%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
CANF Can-Fite BioPharma	0.80%
ORPN Bioblast Pharma	N/A
VCNX Vaccinex	51.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	42.63 million	42.36 million	Not Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable
ORPN Bioblast Pharma	N/A	420,000	N/A	Not Optionable
VCNX Vaccinex	40	2.60 million	1.26 million	No Data

ORPN, CANF, ADXS, and VCNX Headlines

Recent News About These Companies

Vaccinex presents promising cancer treatment data at ASCO

May 29, 2025 | uk.investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025

May 29, 2025 | nasdaq.com

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025 | globenewswire.com

AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finanznachrichten.de

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finance.yahoo.com

Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy

April 22, 2025 | markets.businessinsider.com

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025

April 21, 2025 | quiverquant.comQ

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025 | globenewswire.com

Vaccinex director resigns, no disagreement cited

March 21, 2025 | investing.com

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

March 10, 2025 | finance.yahoo.com

Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 8, 2025 | finanznachrichten.de

Vaccinex to delist common stock from Nasdaq

March 7, 2025 | markets.businessinsider.com

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 7, 2025 | globenewswire.com

Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Vaccinex receives delisting notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Shares Tumble 63% On Nasdaq Delisting

December 17, 2024 | marketwatch.com

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

December 17, 2024 | finance.yahoo.com

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

December 17, 2024 | benzinga.com

Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

December 17, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

ORPN, CANF, ADXS, and VCNX Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.05 0.00 (0.00%)

As of 08/19/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Can-Fite BioPharma NYSE:CANF

$0.66 +0.02 (+3.55%)

Closing price 03:56 PM Eastern

Extended Trading

$0.66 +0.01 (+0.91%)

As of 04:13 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Bioblast Pharma NASDAQ:ORPN

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Vaccinex NASDAQ:VCNX

$0.53 +0.11 (+26.04%)

As of 01:07 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time